PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 201,780 shares, a growth of 77.2% from the June 30th total of 113,864 shares. Based on an average daily volume of 503,315 shares, the short-interest ratio is currently 0.4 days. Approximately 504.5% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PCLA shares. Wall Street Zen upgraded PicoCELA to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings upgraded shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PicoCELA presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in PicoCELA stock. Jane Street Group LLC bought a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned approximately 18.92% of PicoCELA at the end of the most recent quarter.

PicoCELA Stock Performance

Shares of NASDAQ PCLA traded up $0.12 during trading on Thursday, reaching $5.05. The company had a trading volume of 12,112 shares, compared to its average volume of 744,159. PicoCELA has a twelve month low of $1.35 and a twelve month high of $16.80. The stock has a 50-day moving average price of $5.74 and a two-hundred day moving average price of $4.33.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.